Artículo
Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial
Autor/es | Garrido Sánchez, Lucía
Gómez-Revuelta, Marcos Ortiz García de la Foz, Víctor Pelayo-Terán, José María Juncal-Ruiz, María Ruiz Veguilla, Miguel Mayoral-van Son, Jaqueline Ayesa-Arriola, Rosa Vázquez-Bourgon, Javier Crespo Facorro, Benedicto |
Departamento | Universidad de Sevilla. Departamento de Psiquiatría |
Fecha de publicación | 2022-07-27 |
Fecha de depósito | 2023-05-22 |
Publicado en |
|
Resumen | Background
Antipsychotic choice for the acute phase of a first episode of psychosis (FEP) is of the utmost importance since it may influence long-term outcome. However, head-to-head comparisons between second-generation ... Background Antipsychotic choice for the acute phase of a first episode of psychosis (FEP) is of the utmost importance since it may influence long-term outcome. However, head-to-head comparisons between second-generation antipsychotics remain scarce. The aim of this study was to compare the effectiveness in the short term of aripiprazole and risperidone after FEP outbreak. Methods From February 2011 to October 2018, a prospective, randomized, open-label study was undertaken. Two hundred-sixty-six first-episode drug-naïve patients were randomly assigned to aripiprazole (n = 136) or risperidone (n = 130) and followed-up for 12 weeks. The primary effectiveness measure was all-cause treatment discontinuation. In addition, an analysis based on intention-to-treat principle was conducted to assess clinical efficacy. Results The overall dropout rate at 12 weeks was small (6.39%). Effectiveness measures were similar between treatment arms as treatment discontinuation rates (χ 2 = 0,409; P = .522), and mean time to all-cause discontinuation (log rank χ 2 = −1.009; P = .316) showed no statistically significant differences. Despite no statistically significant differences between groups regarding clinical efficacy, aripiprazole required higher chlorpromazine equivalent dosage (χ 2 = 2.160; P = .032) and extended mean time (W = 8183.5; P = .008) to reach clinical response. Sex-related adverse events and rigidity were more frequent in the risperidone group, whereas sialorrhea was on the aripiprazole group. Conclusions No differences regarding effectiveness were found between aripiprazole and risperidone for the short-phase treatment of FEP. Despite the importance of efficacy during this phase, differences in side effect profiles and patient’s preferences are essential factors that may lead clinical decisions for these patients. |
Agencias financiadoras | AstraZeneca Bristol-Myers Squibb Fundacion Marques de Valdecilla Instituto de Salud Carlos III Johnson Johnson Pfizer Plan Nacional de Drogas Research Grant 2005 SENY Fundacio Research Grant |
Identificador del proyecto | API07/011
PI020499 PI050427 PI060507 sco/3246/2004 CI 2005-0,308,007 |
Cita | Garrido Sánchez, L., Gómez-Revuelta, M., Ortiz García de la Foz, V., Pelayo-Terán, J.M., Juncal-Ruiz, M., Ruiz Veguilla, M.,...,Crespo Facorro, B. (2022). Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial. International Journal of Neuropsychopharmacology (IJNP), 25 (11), 900-911. https://doi.org/10.1093/ijnp/pyac047. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Aripiprazole vs Risperidone ... | 1.292Mb | [PDF] | Ver/ | |